AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to higher frequency of adverse events ( compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Probenecid showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · people with chronic gout
Benzbromarone showed no clear difference in serum urate normalisation compared with allopurinol (moderate certainty).
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).
1 finding from 1 review
Total adverse events · people with chronic gout
Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Acute gout attacks · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).
1 finding from 1 review
Pain · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Patient global assessment · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review